Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 48Observational 3Expanded_access 1

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 6Recurrence 3Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Surgical Procedures, Operative 7Liver Transplantation 5Lenalidomide 4Blood Specimen Collection 4pomalidomide 3Neoadjuvant Therapy 3Liquid Biopsy 3gilteritinib 2Therapeutics 2Rituximab 2Proteasome Inhibitors 2Observation 2Mohs Surgery 2Mitomycin 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Immunoconjugates 2High-Throughput Nucleotide Sequencing 2Fluorouracil 2Drug Therapy 2DNA, Mitochondrial 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2Antibodies, Monoclonal 2Antibodies, Bispecific 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1romidepsin 1nedaplatin 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Recurrence × pomalidomide × Clear all
NCT06163040 2025-07-31

A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb

Completed
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03288974 2025-04-15

Pomalyst PMS

Celgene

Completed
397 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02164955 2022-10-20

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Celgene

Completed
775 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚔